-
"Rational Use of Medicines·China Action" 2020 National Experience Exchange Summary and 202...
Time of Update: 2021-05-02
Local health and health administrative departments should take public hospital performance assessment as the starting point to do a good job in industry guidance and supervision; closely focus on the key tasks specified in the "Opinions on Strengthening the Pharmaceutical Management of Medical Institutions to Promote the Rational Use of Drugs".
-
Two major products of Yuanda Pharmaceutical have achieved milestone progress
Time of Update: 2021-05-02
On April 19, 2021, Broad Pharmaceuticals announced that, as a research and development platform in the field of tumor immunotherapy and DNA technology of Broad Pharmaceuticals, OncoSec Medical Incorporated (OncoSec, an associate company of Broad Pharmaceuticals) developed by the US Nasdaq-listed company GenPulse™, a new generation of gene electroporation equipment, recently obtained the European Union CE certification.
-
Global ADC Drug Overview: Can Photoimmunotherapy Highlight the Encirclement
Time of Update: 2021-05-02
In recent years, antibody-drug conjugates (ADCs) have been widely sought after due to their excellent clinical performance and market returns, and they have maintained a high degree of enthusiasm for research and development worldwide.
Then use 690nm wavelength near-infrared light to illuminate the tumor site, induce Cetuximab sarotalocan to kill cancer cells and activate the immune response.
-
RDPAC held the 2021 National Cancer Prevention and Treatment Publicity Week and ``Jointly Innovative Drugs...
Time of Update: 2021-05-02
On April 20, the Pharmaceutical Research and Development Industry Committee (RDPAC) of the China Association of Enterprises with Foreign Investment (RDPAC) held the RDPAC 2021 National Tumor Preventi
-
PD-1 immunotherapy drug Tuoyi® urothelial cancer indication approved in China
Time of Update: 2021-05-02
The POLARIS-03 study co-led by the professor showed that among 136 patients with locally advanced or metastatic urothelial carcinoma who had failed platinum-containing chemotherapy, including neoadjuvant or adjuvant chemotherapy, had progressed within 12 months by independent center imaging (IRC) Assessed, the objective response rate (ORR) of the overall population was 27.
-
Cooperation | Inventory of blockbuster transactions of pharmaceutical companies in the oncology field in March
Time of Update: 2021-05-02
On March 18, Pfizer and American biotechnology company Pyxis Oncology (hereinafter referred to as "Pyxis") jointly announced that they have reached a global licensing agreement for two ADC (PYX-201, PYX-203) candidate products.
-
The 500,000 pharmacy special inspection is coming
Time of Update: 2021-05-02
In addition, judging from the documents issued by Zhejiang, Shanxi, Anhui and other provinces, the focus is on the fundamental orientation of the "four strictest", which also means that this year’s inspections and penalties will be very strict, and retail pharmacies will be severely affected if they violate regulations.
-
Microchip's "Cioroni Capsule" launches Phase III clinical trial for small cell lung cancer
Time of Update: 2021-05-02
Recently, the Insight database revealed that Microchip Bio-Sioroni Capsules has launched a Phase III clinical trial for the treatment of small cell lung cancer that has progressed or recurred after a 2-line system of chemotherapy.
-
2021 AACR: Bayer plans to announce iNHL Phase III clinical data and its...
Time of Update: 2021-05-02
The data is based on a phase III randomized, double-blind, placebo-controlled clinical study that uses Aliqopa® (copanlisib) combined with rituximab intravenous administration to treat patients with relapsed painless non-Hodgkin’s lymphoma (iNHL) for ≥1 course Later relapse, including rituximab (CHRONOS-3).
-
Microcore Bio-Cidabenamine Lung Cancer Phase 2 Clinical Accepted, Cioroni Approved in China and the U.S.
Time of Update: 2021-05-02
On April 20, Microchip released an announcement that the phase 2 trial of chidamide combined with envolimab in the treatment of non-small cell lung cancer (NSCLC) patients who have been treated with PD-1 inhibitors has been received by the Chinese government.
-
Loratinib was used in NSCLC patients with brain metastases after treatment, and the intracranial ORR reached 51.6%!
Time of Update: 2021-04-28
Recently, researchers announced the results of a multi-cohort study aimed at exploring the efficacy and safety of loratinib in the treatment of advanced NSCLC patients who have progressed through the second-generation ALK-TKI treatment.
-
Freshly released | 2021 SGO LBA blockbuster research solves the mystery!
Time of Update: 2021-04-28
The study aims to explore the efficacy and safety of olaparib, olaparib+cediranib versus cediranib as a single agent for endometrial cancer patients.
The Phase Ib KEYNOTE-028 study showed that pembrolizumab showed certain anti-tumor activity in PD-L1-positive vulvar cancer patients with an ORR of 6%.
-
The research team of He Housheng/Wei Gonghong/Ren Shancheng collaborated to discover a new mechanism for regulating prostate cancer
Time of Update: 2021-04-28
On March 19, Professor Ren Shancheng from Shanghai Changhai Hospital, Professor Wei Gonghong from Fudan University School of Basic Medicine and Affiliated Tumor Hospital (formerly at the University of Oulu, Finland), and Professor He Housheng from the University of Toronto in Canada teamed up in Nature Communications An article published in the journal CRISPRi screens reveals a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer.
-
Thinking from a clinical perspective: mechanism research + focus on the crowd + large samples, perfect!
Time of Update: 2021-04-28
Figure 2 Cox regression analysis of IFNα, IFNγ, TNFα and TGFβ pathways and different subtypes of breast cancer recurrence risk.
-
Professor Zijun Liao: Clinical practice has proven that recombinant human endostatin is effective and safe in the treatment of malignant serous effusion
Time of Update: 2021-04-28
Professor Liao Zijun pointed out that “20%~25% of patients who are newly diagnosed with lung cancer in clinical practice are early stage, 70%~75% are middle-advanced stage, malignant serous effusion is a common comorbidity of middle-advanced stage lung cancer.
-
Higher activity than existing targeted drugs, new expectations for ovarian cancer, fallopian tube cancer and peritoneal cancer
Time of Update: 2021-04-28
For a long time in global clinical trials, we have been studying targeted drugs for tumor driver genes, such as directly anchoring EGFR or ALK gene mutations, and inhibiting tumors through the combination of drugs with proteins translated by the mutant genes.
-
Pembrolizumab sequential AVD treatment of newly diagnosed cHL has amazing efficacy
Time of Update: 2021-04-28
The preliminary analysis results of the study reported at the 2019 ASH Annual Meeting showed that after patients received PEM and sequential 2-cycle AVD treatment, the complete metabolic remission (CMR) rate according to mid-term PET-CT assessment reached 100%.
-
JCO: Lower dose, side effects halved, just as effective! Classic breast cancer prevention drugs are expected to benefit more women
Time of Update: 2021-04-28
At the same time, tamoxifen is also approved for the adjuvant treatment of breast cancer, which can significantly reduce the risk of postoperative recurrence.
02598[2] Lower dose of estrogen receptor modulator seems to reduce risk of breast cancer.
-
The upgraded version of "Starve Cancer Cells" is here! Scientists have discovered that a drug can inhibit the growth of melanoma, which is also applicable to other cancers
Time of Update: 2021-04-28
This article is converted Medicine original, reproduced please indicate the source Author: Yun Introduction: Recently, scientists have identified a candidate drug that can prevent cancer cell uptake of glutamine, and can slow the growth of melanoma.
-
Inhibitory leukocyte immunoglobulin-like receptors (LILRBs)
Time of Update: 2021-04-28
Image source: Reference 5 Based on the in-depth understanding of the target and the study of the structure, Kai Tu Biology has developed a series of LILRB family proteins, domains, and different polymer forms of the ligand HLA-G protein to help the research of differentiated antibodies.
